CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$290.64 million for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2014-12-27 was -$66.41M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2014-09-27 was $43.88M, a 2.71% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2014-06-28 was $50.54M, a 37.16% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2013-12-28 was -$75.32M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$290.64M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$290.31M, a 256.36% decline from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $185.67M, a 33.71% decline from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was $280.07M, a 116.11% increase from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 3 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 6 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 9 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|---|---|---|
| 2025-12-27 | -$290.64M 10-K · filed 2026-02-18 | |||
| 2024-12-28 | -$290.31M 10-K · filed 2026-02-18 | |||
| 2023-12-30 | $185.67M 10-K · filed 2026-02-18 | |||
| 2022-12-31 | $280.07M 10-K · filed 2025-02-19 | |||
| 2021-12-25 | $129.60M 10-K · filed 2024-02-14 | |||
| 2020-12-26 | $226.94M 10-K · filed 2023-02-22 | |||
| 2019-12-28 | $108.33M 10-K · filed 2022-02-16 | |||
| 2018-12-29 | $95.06M 10-K · filed 2021-02-17 | |||
| 2017-12-30 | $123.90M 10-K · filed 2020-02-11 | |||
| 2016-12-31 | $59.26M 10-K · filed 2019-02-13 | |||
| 2015-12-26 | $76.16M 10-K · filed 2018-02-13 | |||
| 2014-12-27 | -$66.41M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | -$22.52M derived: sum of 2 quarters · filed 2017-02-14 | $28.02M derived: sum of 3 quarters · filed 2017-02-14 | $71.00M 10-K · filed 2017-02-14 |
| 2014-09-27 | $43.88M 10-Q · filed 2014-10-30 | $94.42M derived: sum of 2 quarters · filed 2014-10-30 | $137.41M 10-Q · filed 2014-10-30 | |
| 2014-06-28 | $50.54M 10-Q · filed 2014-08-07 | $93.53M 10-Q · filed 2014-08-07 | ||
| 2013-12-28 | -$75.32M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | -$32.59M derived: sum of 2 quarters · filed 2016-02-12 | $4.25M derived: sum of 3 quarters · filed 2016-02-12 | $39.90M 10-K · filed 2016-02-12 |
| 2013-09-28 | $42.73M 10-Q · filed 2014-10-30 | $79.57M derived: sum of 2 quarters · filed 2014-10-30 | $115.22M 10-Q · filed 2014-10-30 | |
| 2013-06-29 | $36.85M 10-Q · filed 2014-08-07 | $72.50M 10-Q · filed 2014-08-07 | ||
| 2012-12-29 | $35.50M 10-K · filed 2015-02-17 | |||
| 2011-12-31 | $47.16M 10-K · filed 2014-02-25 | |||
| 2010-12-25 | -$149.28M 10-K · filed 2013-02-27 | |||
| 2009-12-26 | $38.37M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |